Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHWAY: Zuranolone in Bipolar Depression
NCT03692910Phase 2Completed
- Sponsor
- Biogen
- Start
- Aug 2018
- Primary completion
- May 2019
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label trial of zuranolone in bipolar disorder (BD) (3 arms), sponsored by Biogen. Primary endpoints: Treatment-Emergent Adverse Events at Day 42, Treatment-Emergent Adverse Events Graded by Severity at Day 42 and 2 more. Started Aug 2018; status: completed.
02
Drugs
zuranolone
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03692910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692910.